Prostheses Infection Clinical Trial
Official title:
English Efficacy and Tolerance of 4 Weeks of Tedizolid in Prosthetic Joint Infections Treated With Implant Removal
To evaluate the efficacy of 4 weeks of 200 mg/24h of tedizolid for prosthetic join infections caused by tedizolid susceptible microorganisms treated with implant removal in one or two stages at 6 months of followup after stopping tedizolid treatment.
To evaluate the efficacy of 4 weeks of 200 mg/24h of tedizolid for prosthetic join infections
caused by tedizolid susceptible microorganisms treated with implant removal in one or two
stages at 6 months of followup after stopping tedizolid treatment.
Secondary objectives:
Evaluate the efficacy of tedizolid at 12 months of follow-up; evaluate the rate of
gastrointestinal adverse events with tedizolid; determine the rate of haematological
abnormalities during tedizolid treatment and; in case of two-stage exchange, the rate of
positive cultures during reimplantation.
;